Dual Inhibition of PARP and ATR Feasible, Early Trials Suggest
April 19, 2023 12:40 pmby Leah Lawrence
Early-phase trials testing the safety and efficacy of PARP inhibition plus ataxia telangiectasia- and Rad3-related kinase (ATR) inhibition in biomarker-selected patients show intriguing results, researchers reported at the AACR Annual Meeting 2023.
“ATR inhibition prevents recovery from … Read more